The rebound continued the growth of the pharmaceutical industry in the third quarter

As of October 18, 177 pharmaceutical listed companies had reported third-quarter earnings forecasts, 103 had increased net profit, 48 had fallen and 26 were uncertain. Overall, the pharmaceutical industry is running smoothly, recovering after experiencing a low growth rate in 2015. Under the influence of fundamental recovery and related policies, many people in the industry believe that the recovery momentum of the pharmaceutical sector is sustainable.rebound continued
Caihui financial statistics show that the above 177 pharmaceutical companies in the first three quarters of this year sales revenue, gross profit, net profit growth of 13%, 18%, 19%, respectively. The trend of improvement in overall performance continued month-on-month. Since the first quarter of 2016, the industry has seen signs of bottoming out, from last year's annual report to this year's semi-annual report, the situation of the third quarter report, the rebound continued.
In terms of revenue and net profit growth in the sub-sectors, the medical services industry is the first to take the lead, which is related to the lower base;
industry insiders told China Securities News that the pharmaceutical industry sector has gradually recovered in the past two years, the long-term bottom or has passed. Starting from the first quarter of 2013, the industry revenue growth rate for the first time out of the 20% growth rate, the industry growth trend from the first quarter of 2013 the chemical industry sector took the lead, in the first quarter of 2014 the Chinese pharmaceutical sector began to decline, to the 2015 half-year report hit a new low growth rate of 8%.35 companies increased their net profit by more than 50 per cent
of the 177 companies, net profit is expected to increase year-on-year to 103. Among them, 35 companies are expected to increase net profit by more than 50%, including Zhifei Bio, Northeast Pharmaceuticals, Lizhu Group, Libang Instruments, Temple of Heaven Biology, Health Yuan, Garden Biology, Zhao Yanxin Pharmaceuticals, Zhendong Pharmaceuticals, Qianshan Pharmaceutical Machine, Four Rings Biology, Yong'an Pharmaceuticals, Kantai Bio, Kaili Medical. The increase in performance was mainly due to the expansion of sales, new profit growth and extended expansion and post-statement earnings growth resulting from the listing of new products.
it is worth mentioning that due to the tightening of environmental protection, many API enterprises stop production restrictions, so that the price of RAW drugs, Northeast Pharmaceuticals, Garden Biology, etc. to achieve a substantial increase in net profit. Qiu Qiu, a pharmaceutical researcher at Huatron Securities, believes that the production capacity of API will be further compressed and the price increase of API is expected to continue.
's 15 companies are expected to see net profit growth of between 30% and 50%, including Fuan Pharmaceuticals, Jianfan Bio, Wuwu Bio, Haichen Pharmaceuticals, Deri Medical, O jiahua, Lepu Medical, Anke Bio, Prypy Pharmaceuticals, Centauri Pharmaceuticals, Dean Diagnostics, etc. Acquisition of assets and statements, sales scale expansion, etc. are important factors in the rise in net profit.
48 companies forecast a decline in net profit, including Haihong Holdings, Yihua Health, Taiji Group, Hepple, Lexi Medical, Guo Nong Technology, Boji Pharmaceuticals, Taihe Health and others.two types of companies have more room for growth
in the past month, the pharmaceutical and biological index rose about 7%, ranking eighth among the 28 first-class industries. In the short term, pharmaceutical stocks have the potential to catch up head-on.
, chief medical researcher at Guoxin Securities, believes that the recent rise in pharmaceutical stocks is sustainable due to a resonance of technical, policy and fundamental factors.
from a technical point of view, the pharmaceutical industry index since 2016 has fallen sharply behind the CSI 300 index and home appliances, food and beverage industries, after 1-2 years of valuation digestion has a basis for growth. From a policy point of view, on October 8th, the relevant policies such as promoting reform of the pharmaceutical industry and encouraging innovation were announced. Fundamentally, the latest data from the National Bureau of Statistics and the Ministry of Industry and Information Technology for 2017 show that profit growth in the pharmaceutical sector has picked up.
Jiang Weina pointed out that the growth space of the two types of companies is large, first of all, demand is rigid, the impact of medical insurance charges is relatively small, and is expected to maintain rapid growth of high-barrier specialty drugs, and second, due to generic drug consistency evaluation brought about by the stock market reshuffle of high-level generic pharmaceutical preparations. (China Securities News)